Galapagos NV's (GLPG) stock plunged in pre-market trading on Wednesday, October 31, 2024, after the biopharmaceutical company reported disappointing financial results for the third quarter of 2024.
The Belgian company reported a quarterly adjusted loss of $0.77 per share, missing analyst expectations of a loss of $0.49 per share. Revenue fell by a steep 50.1% year-over-year to €59.85 million, significantly lower than the consensus estimate of €69.44 million.
Galapagos' underperformance in the quarter, coupled with a 155.7% decline in analyst earnings estimates over the past three months, fueled concerns about the company's financial outlook. The pre-market sell-off reflects investors' disappointment with the company's failure to meet market expectations and the potential challenges it faces in the near future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.